So, NRF2 has been identified as one such mechanism, hence probably counteracting repressor signals and providing a tumor growth advantage, concluding that an efficient therapy for GBM must consider that high NFR2 and WWTR1 levels are predictors of chemoresistance [185]. The gene discussed is WWTR1; the disease is glioblastoma.